Statement: the primary trial and the secondary trial are testing completely different modalities of interventions, but utilising the same 21 day cycle.
Primary_evidence: INTERVENTION 1:    Treatment (Tivantinib)   Patients receive tivantinib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection at baseline and periodically during study for c-Met expression, relevant markers (HGF and VEGF), PTEN loss, and PI3K mutation analysis by FISH and IHC. Archived tumor tissue samples are also analyzed.   Laboratory Biomarker Analysis: Correlative studies   Tivantinib: Given PO
Secondary_evidence: INTERVENTION 1:    Prone Prone position INTERVENTION 2:    Supine Supine position